Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program – GlobeNewswire
– Company cost structure expected to be reduced by $70 to $75 million in 2019 – Approximately $100 million in cash and marketable securities at December 31, 2018 DUBLIN, Ireland, Feb. 07, 2019 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), today announced a corporate restructuring to assure the financial health required to maximize the…